{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T17:19:20Z","timestamp":1792343960041,"version":"4.4.0"},"reference-count":18,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T00:00:00Z","timestamp":1701129600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:p>A 28-year-old man was admitted to our psychiatric ward with severe obsessive-compulsive disorder (OCD) and comorbid depression. At intake, obsessive-compulsive symptoms were present most time of the day and were related to an intense fear of causing interpersonal misunderstandings. Various treatment attempts, including cognitive-behavioural therapy (CBT) with exposure and response prevention (ERP), selective serotonin reuptake inhibitors, clomipramine, and add-on antipsychotics were either ineffective and\/or were not tolerated, and the patient\u2019s condition worsened progressively. Following an in-depth multidisciplinary team discussion and a shared decision-making process, an off-label treatment trial with esketamine and concomitant psychotherapy was started. The patient received 10 esketamine\u2009+\u2009psychotherapy sessions over a period of about 2\u2009months, followed by two maintenance sessions in about 3-week intervals. After this, he was discharged into regular outpatient care where he continued to receive maintenance esketamine treatment every 4\u20136\u2009weeks and, independent of this, individual CBT. Following the establishment of esketamine with concurrent psychotherapy, the patient exhibited a remarkable clinical improvement. Obsessive-compulsive symptoms showed a clear and sustained response (Y-BOCS before treatment &amp;gt;35, Y-BOCS at week 8\u2009=\u200923, Y-BOCS at week 26\u2009=\u200914). Paralleling this, depressive symptoms also decreased (MADRS before treatment\u2009=\u200947, MADRS at week 9\u2009=\u200912, MADRS at week 26\u2009=\u20093). At a naturalistic follow-up at week 66, obsessive-compulsive symptoms were still mild (Y-BOCS\u2009=\u200913), and depression was still in remission (MADRS\u2009&amp;lt;\u20096). This clinical case suggests that (es)ketamine plus concomitant psychotherapy may hold promise as a therapeutic strategy for difficult-to-treat OCD and depression and its full clinical potential should be evaluated in more comprehensive future studies.<\/jats:p>","DOI":"10.3389\/fpsyt.2023.1291077","type":"journal-article","created":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T01:01:46Z","timestamp":1701133306000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Clinical case report: considerable improvement of severe and difficult-to-treat obsessive-compulsive disorder with comorbid depression under treatment with esketamine and concomitant psychotherapy"],"prefix":"10.3389","volume":"14","author":[{"given":"Alexander","family":"Kaltenboeck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Foerster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Strafner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Demal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilufar","family":"Mossaheb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Friedrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,11,28]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ajp.2016.02.001","article-title":"Adult obsessive\u2013compulsive disorder and quality of life outcomes: a systematic review and meta-analysis","volume":"22","author":"Coluccia","year":"2016","journal-title":"Asian J Psychiatr"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/s41572-019-0102-3","article-title":"Obsessive\u2013compulsive disorder","volume":"5","author":"Stein","year":"2019","journal-title":"Nat Rev Dis Prim"},{"key":"ref3","author":"Voderholzer","year":"2022"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"e37833","DOI":"10.7759\/cureus.37833","article-title":"Clinical effectiveness of N-methyl-D-aspartate (NMDA) receptor antagonists in adult obsessive-compulsive disorder (OCD) treatment: a systematic review","volume":"15","author":"Ferguson","year":"2023","journal-title":"Cureus"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"308","DOI":"10.3928\/00485713-20150602-06","article-title":"Glutamate modulators in the treatment of obsessive-compulsive disorder","volume":"45","author":"Pittenger","year":"2015","journal-title":"Psychiatr Ann"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"102183","DOI":"10.1016\/j.ajp.2020.102183","article-title":"Clinical utility of repeated intravenous ketamine treatment for resistant obsessive-compulsive disorder","volume":"52","author":"Sharma","year":"2020","journal-title":"Asian J Psychiatr"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-023-01632-1","article-title":"Ketamine in neuropsychiatric disorders: an update","author":"Johnston","year":"2023","journal-title":"Neuropsychopharmacology"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1097\/HRP.0000000000000330","article-title":"Ketamine in the treatment of obsessive-compulsive disorder: a systematic review","volume":"30","author":"Bandeira","year":"2022","journal-title":"Harv Rev Psychiatry"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"856","DOI":"10.3390\/brainsci11070856","article-title":"Therapeutic potentials of ketamine and Esketamine in obsessive\u2013compulsive disorder (OCD), substance use disorders (SUD) and eating disorders (ED): a review of the current literature","volume":"11","author":"Martinotti","year":"2021","journal-title":"Brain Sci"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"567","DOI":"10.4088\/JCP.10l06653","article-title":"Rapid resolution of obsessions after an infusion of intravenous ketamine in a patient with treatment-resistant obsessive-compulsive disorder","volume":"72","author":"Rodriguez","year":"2011","journal-title":"J Clin Psychiatry"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1038\/npp.2013.150","article-title":"Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept","volume":"38","author":"Rodriguez","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.2147\/JPR.S360733","article-title":"Ketamine assisted psychotherapy: a systematic narrative review of the literature","volume":"15","author":"Drozdz","year":"2022","journal-title":"J Pain Res"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"e79","DOI":"10.1192\/bjo.2023.53","article-title":"Ketamine and psychotherapy for the treatment of psychiatric disorders: systematic review","volume":"9","author":"Kew","year":"2023","journal-title":"BJPsych Open"},{"key":"ref14","first-page":"9","article-title":"Ketamine augmentation of exposure response prevention therapy for obsessive-compulsive disorder","volume":"18","author":"Bottemanne","year":"2021","journal-title":"Innov Clin Neurosci"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jad.2022.07.030","article-title":"Active mechanisms of ketamine-assisted psychotherapy: a systematic review","volume":"315","author":"Joneborg","year":"2022","journal-title":"J Affect Disord"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1159\/000517074","article-title":"Cognitive Behavioral therapy to sustain the antidepressant effects of ketamine in treatment-resistant depression: a randomized clinical trial","volume":"90","author":"Wilkinson","year":"2021","journal-title":"Psychother Psychosom"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1097\/JCP.0000000000000659","article-title":"Intranasal ketamine and cognitive-Behavioral therapy for treatment-refractory obsessive-compulsive disorder","volume":"37","author":"Adams","year":"2017","journal-title":"J Clin Psychopharmacol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"408","DOI":"10.4088\/JCP.15l10138","article-title":"Can exposure-based CBT extend the effects of intravenous ketamine in obsessive-compulsive disorder?: an open-label trial","volume":"77","author":"Rodriguez","year":"2016","journal-title":"J Clin Psychiatry"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2023.1291077\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T01:01:52Z","timestamp":1701133312000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2023.1291077\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,28]]},"references-count":18,"alternative-id":["10.3389\/fpsyt.2023.1291077"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2023.1291077","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,28]]},"article-number":"1291077"}}